Bio-ink development for three-dimensional bioprinting of hetero-cellular cartilage constructs
Mouser, Vivian H M; Levato, Riccardo; Mensinga, Anneloes; Dhert, Wouter J A; Gawlitta, Debby; Malda, Jos
(2020) Connective tissue research, volume 61, issue 2, pp. 137 - 151
(Article)
Abstract
Bioprinting is a promising tool to fabricate organized cartilage. This study aimed to investigate the printability of gelatin-methacryloyl/gellan gum (gelMA/gellan) hydrogels with and without methacrylated hyaluronic acid (HAMA), and to explore (zone-specific) chondrogenesis of chondrocytes, articular cartilage progenitor cells (ACPCs), and multipotent mesenchymal stromal cells (MSCs) embedded in these bio-inks.
... read more
The incorporating of HAMA in gelMA/gellan bio-ink increased filament stability, as measured using a filament collapse assay, but did not influence (zone-specific) chondrogenesis of any of the cell types. Highest chondrogenic potential was observed for MSCs, followed by ACPCs, which displayed relatively high proteoglycan IV mRNA levels. Therefore, two-zone constructs were printed with gelMA/gellan/HAMA containing ACPCs in the superficial region and MSCs in the middle/deep region. Chondrogenic differentiation was confirmed, however, printing influence cellular differentiation. ACPC- and MSC-laden gelMA/gellan/HAMA hydrogels are of interest for the fabrication of cartilage constructs. Nevertheless, this study underscores the need for careful evaluation of the effects of printing on cellular differentiation.
show less
Download/Full Text
Keywords: Chondroprogenitor cells, GelMA/gellan, hyaluronic acid, mesenchymal stromal cells, zonal cartilage, Rheumatology, Biochemistry, Orthopedics and Sports Medicine, Molecular Biology, Cell Biology
ISSN: 0300-8207
Publisher: Informa Healthcare
Note: Funding Information: The research leading to these results has received funding from the European Community?s Seventh Framework Programme (FP7/2007-2013) under grant agreement n?309962 (HydroZONES), the European Research Council under grant agreement 647426 (3D-JOINT), and the Dutch Arthritis Foundation (LLP-12). The authors would like to thank J. Rudman for his help with the cell cultures, M. H. P. van Rijen for his help with the histology, and A. Abbadessa for the synthesis of HAMA. The primary antibody against collagen type II (II-II6B3) and collagen type VI (5C6), developed by T. F. Linsenmayer and E. S. Engvall, respectively, were obtained from the DSHB, developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biology, Iowa City, IA 52242. Funding Information: The research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 309962 (HydroZONES), the European Research Council under grant agreement 647426 (3D-JOINT), and the Dutch Arthritis Foundation (LLP-12). Publisher Copyright: © 2018, © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
(Peer reviewed)
